Anti-Leishmania activity of essential oil of Myracrodruon urundeuva (Engl.) Fr. All.: Composition, cytotoxity and possible mechanisms of action.

Myracrodruon urundeuva (Engl.) Fr. All., commonly known as "aroeira-do-sertão", is a medicinal plant from Anacardiaceae family. In this study, the chemical composition of M. urundeuva essential oil (MuEO) was evaluated by gas chromatography-mass spectrometry (GC-MS), as well as its anti-Leishmania potential, cytotoxicity, and macrophage activation capability as possible antiprotozoal mechanism of action were assessed. Fourteen compounds were identified, which constituted 94.87% of total oil composition. The most abundant components were monoterpenes (80.35%), with ß-myrcene (42.46%), α-myrcene (37.23%), and caryophyllene (4.28%) as the major constituents. The MuEO inhibited the growth of promastigotes (IC50 205 ± 13.4 µg mL-1), axenic amastigotes (IC50 104.5 ± 11.82 µg mL-1) and decreased percentage of macrophage infection and number of amastigotes per macrophage (IC50 of 44.5 ± 4.37 µg⋅mL-1), suggesting significant anti-Leishmania activity. The cytotoxicity of MuEO was assessed by MTT test in Balb/c murine macrophages and by human erythrocytes lysis assay and low cytotoxicity for these cells was observed. The CC50 value against macrophages were 550 ± 29.21 µg mL-1, while cytotoxicity for erythrocytes was around 20% at the highest concentration assessed, with HC50 > 800 µg mL-1. While MuEO-induced anti-Leishmania activity is not mediated by increases in both lysosomal activity and nitric oxide production in macrophages, the results suggest the antiamastigote activity is associated with an immunomodulatory activity of macrophages due to an increase of phagocytic capability induced by MuEO. Thus, MuEO presented significant activity against Leishmania amazonensis, probably modulating the activation of macrophages, with low cytotoxicity to murine macrophages and human erythrocytes.

Emulsões O/A contendo Cetoconazol 2,0%: avaliação da estabilidade acelerada e estudos de liberação in vitro / O/W Emulsion Containing 2.0% Ketoconazole: Accelerated Stability Test and in vitro Release

Os objetivos do estudo foram desenvolver e avaliar a estabilidade físico-química de emulsões O/A contendo cetoconazol a 2,0% e determinar seu perfil de liberação in vitro. As formulações foram preparadas com bases auto-emulsionáveis com diferentes características químicas. A estabilidade do sistema foi avaliada de acordo com o Guia para Realização de Testes de Estabilidade em Produtos Farmacêuticos, utilizando diferentes temperaturas (4ºC, 37ºC e 45ºC) por um período de tempo de três meses. Os parâmetros avaliados durante o ensaio foram: as características organolépticas,o pH, o comportamento reológico e a concentração do ativo. A emulsão considerada estável foi submetida ao ensaio de liberação in vitro utilizando célula de difusão de Franz. A quantificação do cetoconazol na formulação e na solução receptora foi realizada por método espectrofotométrico no ultravioleta a 244 nm. Dentre as formulações testadas, somente aquela preparada com álcool cetoestearílico e estearato de polietilenoglicol (PEG20) manteve suas características físico-químicas estáveis durante o teste. O estudo de liberação in vitro demonstrou que o fármaco foi liberado do sistema gradualmente no decorrer do tempo, apresentando uma cinética pseudo zero ordem.

The goal of this work was to develop and assess the physicochemical stability of O/W emulsions containing 2.0% ketoconazole and to determine their in vitro release profile. These formulations were prepared with self-emulsifying bases that differed in their chemical characteristics. The stability of the system was assessed, as recommended in the Guide to Drug Product Stability Tests, over 3 months at 3 different temperatures (4ºC, 37ºC and 45ºC). The characteristics assessed during the test were the organoleptic properties, pH, rheological behavior and drug concentration. The most stable emulsion was subjected to an in vitro release test in a Franz diffusion cell system. The ketoconazole in both the formulation and receptor phase was determined by UV spectrophotometry at 244 nm. The O/W emulsion prepared with cetearyl alcohol and polyethylene glycol (PEG20) stearate was the only one that maintained its physicochemical characteristics throughout the test. The in vitro release test demonstrated that the drug was released gradually, exhibiting pseudo zero-order kinetics.

Masseter muscles electromyography study of individuals with and without malocclusion during dental clenching.

The present study had as an objective to verify the electromyographic activity of the masseter muscles during intercuspal maximal clenching in individuals with and without malocclusion. For such purpose, 37 individuals participated, constituting three distinct groups according to the classification of the occlusion: 9 individuals with clinically normal occlusion (G1), 17 individuals with Angle Class I malocclusion (G2) and 11 individuals with Angle Class II division 1 malocclusion (G3). Allparticipants were female, between the ages of 20 years, 7 months to 30 years, 8 months, with permanent natural teeth. The selection of the individuals was made with the application of a specific protocol, being complemented with an oral clinical myofunctional exam. The activity of the bilateral muscle masseter was investigated, in its superficial portion, by means of electromyographic evaluation with surface electrodes. Three consecutive intercuspal maximal clenching were recorded. The results showed that there was not significant statistical difference from the eletromyographic activity between the three groups. The conclusion was that the malocclusion did not interfere in the eletromyographic activity of the masseter muscles.